RCT of rapamycin versus placebo for safety and feasibility in APOE4 carriers at Alzheimer's risk
This randomized controlled trial evaluated the safety, feasibility, and preliminary efficacy of low-dose daily rapamycin (1 mg) or fasting-mimicking diet (FMD) compared to placebo over 8 weeks in middle-aged adults carrying the APOE ε4 allele, a genetic risk factor for Alzheimer's disease. The study aimed to assess outcomes related to body, brain, and longevity in this at-risk population. No results of the intervention were reported in the abstract provided.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 16, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 2 months
- Population
- Middle-aged adults at elevated risk for Alzheimer's disease due to the apolipoprotein (APOE) ε4 allele
- Primary outcome
- Safety, feasibility, and preliminary efficacy
- Effect size
- —
- Significance
- Not reported
- Journal
- Cedars-Sinai Medical Center
- Published
- Sep 16, 2026
Sources
Primary source
- Cedars-Sinai Medical Center ↗Clinical trial
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.